OSIPI Strategy Board
The Strategy Board (SB) represents the stakeholders within OSIPI and maintains the Strategic Plan outlining the mission, aims and general approach of OSIPI. If needed the SB will also propose changes to the OSIPI governance for approval by the ISMRM perfusion study group.
The SB consists of the OSIPI leadership team, the perfusion study group governing committee, and any number of advisory members representing other bodies with an interest in perfusion open source software. This could include other ISMRM study groups, other societies or more informal networks.
If you are interested to represent an external body within the SB, please contact the OSIPI chair.
OSIPI Strategic Plan
- Current version 1.0
- Current draft version. Please feel free to add comments and suggestions to be considered at the next SB meeting.
OSIPI Governance
- Current version 1.0
- Current draft version. Please feel free to add comments and suggestions to be considered at the next SB meeting.
Current SB members
- Steven Sourbron (OSIPI chair and perfusion study group chair)
- Laura Bell (OSIPI vice chair)
- Henk-Jan Mutsaerts (OSIPI secretary)
- Xavier Golay (Perfusion study group - past Chair)
- Hanzhang Lu (Perfusion study group - vice chair)
- Maria A. Fernandez-Seara (Perfusion study group - secretary)
- Xingfeng Shao (Perfusion study group - trainee representative)
- Caroline Chung (Co-chair, QIBA DCE-MRI Biomarker Committee)
- Hendrik Laue (Co-chair, QIBA DCE-MRI Biomarker Committee)
- Ona Wu (Co-chair, QIBA DSC-MRI Biomarker Committee)
- Fernando Calamante (ISMRM president-elect)
- Matthias Guenther(co-chair, EIBIR/QIBA ASL Biomarker Ctte)
SB meetings
- The first SB meeting will take place in may 2021 around the time of the ISMRM meeting in Vancouver.
SB links
- Members-only documents